Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

PZ0183

Sigma-Aldrich

ERB-041

≥98% (HPLC)

Sinonimo/i:

2-(3-Fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, Prinaberel, WAY-202041

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C15H10FNO3
Numero CAS:
524684-52-4
Peso molecolare:
271.24
Numero MDL:
MFCD09954141
Codice UNSPSC:
51111800
ID PubChem:
329823757
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to tan

Solubilità

DMSO: ≥25 mg/mL

Temperatura di conservazione

room temp

Stringa SMILE

OC(C=C1)=C(F)C=C1C2=NC3=CC(O)=CC(C=C)=C3O2

InChI

1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,18-19H,1H2
MQIMZDXIAHJKQP-UHFFFAOYSA-N

Informazioni sul gene

human ... ESR2(2100)

Azioni biochim/fisiol

ERB-041 is a potent, selective ERβ receptor agonist (IC50 ERβ: 5.4 nM; > 200-fold selective over ERα)
ERB-041 is a potent, selective estrogen ERβ receptor agonist (IC50 ERβ: 5.4 nM; > 200-fold selective over ERα). ERβ plays a minor role in mediating estrogen action in the uterus, the hypothalamus/pituitary, the skeleton, and other classic estrogen target tissues. However, a clear role for ERβ has been established in the ovary, cardiovascular system, and brain as well as in animal models of inflammation including arthritis, endometriosis, inflammatory bowel disease, and sepsis. There is increasing interest in finding ERβ agonists for potential use in a variety of clinical applications without triggering classic estrogenic side effects.

Caratteristiche e vantaggi

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302,H319

Classi di pericolo

Acute Tox. 4 Oral - Eye Irrit. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000156769
0000156768
0000081316

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Sreenivasan Paruthiyil et al.
PloS one, 4(7), e6271-e6271 (2009-07-18)
Estrogens produce biological effects by interacting with two estrogen receptors, ERalpha and ERbeta. Drugs that selectively target ERalpha or ERbeta might be safer for conditions that have been traditionally treated with non-selective estrogens. Several synthetic and natural ERbeta-selective compounds have
Iuliia Savchuk et al.
PloS one, 8(8), e71722-e71722 (2013-08-24)
It is well known that estrogens and estrogen-like endocrine disruptors can suppress steroidogenic gene expression, attenuate androgen production and decrease differentiation of adult Leydig cell lineage. However, there is no information about the possible link between the potency of Leydig
Qian Jiang et al.
Purinergic signalling, 13(1), 105-117 (2016-11-07)
Estrogen receptor beta (ERβ) has been shown to play a therapeutic role in inflammatory bowel disease (IBD). However, the mechanism underlying how ERβ exerts therapeutic effects and its relationship with P2X3 receptors (P2X3R) in rats with inflammation is not known.
Geriolda Topi et al.
The Journal of pathology, 251(3), 297-309 (2020-04-26)
Oestrogen receptor β (ERβ) has been suggested to have anti-proliferative and anti-tumour effects in breast and prostate cancer cells, but other studies have indicated its tumour-promoting effects. Understanding the complex effects of this receptor in different contexts requires further study.
Ana Paola G Lombardi et al.
Frontiers in endocrinology, 11, 184-184 (2020-04-25)
Prostate cancer is initially dependent on the androgen, gradually evolves into an androgen-independent form of the disease, also known as castration-resistant prostate cancer (CRPC). At this stage, current therapies scantily improve survival of the patient. Androgens and estrogens are involved
Visualizza tutti i documenti correlati

Articoli

Nuclear Receptors (Steroids)

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.